UEUri Elia

Uri Elia

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Uri Elia has a total of 47 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A single-dose membrane-anchored F1/LcrV mRNA vaccine confers protection against pneumonic plague: a preclinical study

    by Hila Cohen, Yinon Levy, David Gur, Hani Dekel Jaoui, Einat Bleiberg Vitner, Shlomi Lazar, Liat Bar-On, Moshe Aftalion, Ma’AYan Israeli, Adi Bercovich-Kinori, et al.

  • Top Cited Papers

    Challenges and opportunities in mRNA vaccine development against bacteria

    by Ilke Aernout, Rein Verbeke, Fabien Thery, Patrick Willems, Uri Elia, Stefaan C. De Smedt, Rino Rappuoli, Dan Peer, Francis Impens, Ine Lentacker

    The global surge in antimicrobial resistance presents a critical threat to public health, emphasizing the urgent need for the development of new and more effective bacterial vaccines. Since the success of mRNA vaccines during the COVID-19 pandemic, this vaccine strategy has rapidly advanced, with most efforts focused on cancer immunotherapy and targeting viral pathogens. Recently, mRNA vaccines have entered the early phases of clinical development for bacterial diseases. However, bacteria present greater biological complexity compared with viruses, posing additional challenges for vaccine design, such as antigen selection, immune response and mRNA construct design. Here, we discuss critical aspects in the development of bacterial mRNA vaccines, from antigen selection to construct design. We also highlight the current preclinical landscape and discuss remaining translational challenges and future potential for mRNA vaccines against bacterial infections.


  • Open Access

    Novel Bivalent mRNA‐LNP Vaccine for Highly Effective Protection against Pneumonic Plague

    by Uri Elia, Yinon Levy, Hila Cohen, Ayelet Zauberman, David Gur, Inbal Hazan‐Halevy, Moshe Aftalion, Shani Benarroch, Erez Bar‐Haim, Orit Redy‐Keisar, et al.

    Yersinia pestis , the causative agent of plague, remains a significant global health hazard and a potential top‐tier biothreat despite modern medical advances. Here, two mRNA constructs encoding different versions of the low‐calcium response virulence (LcrV) protective antigen, an essential virulence factor of Y. pestis , are designed and evaluated. Next, the immunogenicity and protective efficacy both independently and in combination is assessed with the previously reported F1‐encoding mRNA construct in the well‐established mouse model of pneumonic plague. The findings reveal that human Fc‐conjugated F1 + LcrV combination mRNA vaccination resulted in significant immune activation and substantial protection against intranasal Y. pestis challenge. Notably, the combined vaccine demonstrates protective efficacy against two highly virulent wild‐type Y. pestis strains representing distinct biovars and an atypical, unencapsulated strain. This study represents the first comprehensive evaluation of mRNA constructs encoding innovatively designed versions of LcrV and F1 for pneumonic plague prevention, addressing critical gaps in current vaccination approaches. This study establishes the mRNA‐lipid nanoparticle (LNP) platform as a promising tool for addressing bacterial pathogens, including those resistant to antibiotics. By broadening its applicability to diverse threats, this technology represents an innovative approach to tackling some of the most pressing challenges in global health.


  • Top Cited Papers

    A single-dose F1-based mRNA-LNP vaccine provides protection against the lethal plague bacterium

    by Edo Kon, Yinon Levy, Uri Elia, Hila Cohen, Inbal Hazan-Halevy, Moshe Aftalion, Assaf Ezra, Erez Bar-Haim, Gonna Somu Naidu, Yael Diesendruck, et al.

    Messenger RNA (mRNA) lipid nanoparticle (LNP) vaccines have emerged as an effective vaccination strategy. Although currently applied toward viral pathogens, data concerning the platform’s effectiveness against bacterial pathogens are limited. Here, we developed an effective mRNA-LNP vaccine against a lethal bacterial pathogen by optimizing mRNA payload guanine and cytosine content and antigen design. We designed a nucleoside-modified mRNA-LNP vaccine based on the bacterial F1 capsule antigen, a major protective component of Yersinia pestis , the etiological agent of plague. Plague is a rapidly deteriorating contagious disease that has killed millions of people during the history of humankind. Now, the disease is treated effectively with antibiotics; however, in the case of a multiple-antibiotic-resistant strain outbreak, alternative countermeasures are required. Our mRNA-LNP vaccine elicited humoral and cellular immunological responses in C57BL/6 mice and conferred rapid, full protection against lethal Y. pestis infection after a single dose. These data open avenues for urgently needed effective antibacterial vaccines.


  • Lipid Nanoparticle RBD-hFc mRNA Vaccine Protects hACE2 Transgenic Mice against a Lethal SARS-CoV-2 Infection

    by Uri Elia, Shahar Rotem, Erez Bar-Haim, Srinivas Ramishetti, Gonna Somu Naidu, David Gur, Moshe Aftalion, Ma’aYan Israeli, Adi Bercovich-Kinori, Ron Alcalay, et al.

    The COVID-19 pandemic led to development of mRNA vaccines, which became a leading anti-SARS-CoV-2 immunization platform. Preclinical studies are limited to infection-prone animals such as hamsters and monkeys in which protective efficacy of vaccines cannot be fully appreciated. We recently reported a SARS-CoV-2 human Fc-conjugated receptor-binding domain (RBD-hFc) mRNA vaccine delivered via lipid nanoparticles (LNPs). BALB/c mice demonstrated specific immunologic responses following RBD-hFc mRNA vaccination. Now, we evaluated the protective effect of this RBD-hFc mRNA vaccine by employing the K18 human angiotensin-converting enzyme 2 (K18-hACE2) mouse model. Administration of an RBD-hFc mRNA vaccine to K18-hACE2 mice resulted in robust humoral responses comprising binding and neutralizing antibodies. In correlation with this response, 70% of vaccinated mice withstood a lethal SARS-CoV-2 dose, while all control animals succumbed to infection. To the best of our knowledge, this is the first nonreplicating mRNA vaccine study reporting protection of K18-hACE2 against a lethal SARS-CoV-2 infection.